Market reports & researches
LOG IN | Services | Contact | Custom Research



Main Healthcare, Pharmaceuticals & Biotechnology Healthcare and drugs DNA Probes-based Diagnostics - Global Strategic Business Report
Publications

(Currently 512486 Items)


Partners


Healthcare and drugs / REPORT INFORMATION

DNA Probes-based Diagnostics - Global Strategic Business Report

DateAug, 2006
Pages347
Price / format€2611 / Hard Copy
€2611 / Electronic

€2 611 

Report Information | Custom-Tailored Research | Product Trade Lead


Abstract:
 This report analyzes the worldwide markets for DNA Probes-based Diagnostics in Millions of US$. The specific end-use segments discussed are Infectious Diseases, Cancer Testing, Genetic Predisposition, Identity/Forensics, and Molecular HLA (Human Leukocyte Antigen) Typing. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Latin America. Annual forecasts are provided for each region for the period of 2000 through 2010. The report profiles 46 companies including many key and niche players worldwide such as Abbott Laboratories, Affymetrix Inc., Applied Biosystems Group, Bayer Diagnostics, Becton Dickinson & Company, Beckman Coulter, bioMerieux, Biogenex Laboratories, Celera Genomics, Digene Corporation, Gen-Probe Inc, Genzyme Corp, MP Biomedicals, Roche Diagnostics, and Tm Bioscience. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks.

For information on site licence pricing please click on Enquire Before Buying








Table of contents:
 DNA PROBES-BASED DIAGNOSTICS
A GLOBAL STRATEGIC BUSINESS REPORT


CONTENTS



I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-2
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3
Infectious Diseases I-3
Cancer I-4
Genetic Predisposition I-4
Identity/Forensics I-4
Molecular HLA Testing I-4
Other Diagnostic Applications I-4


II.
1. Market Dynamics II-1
Industry Overview II-1
DNA Probes: Robust Growth Ahead II-1
Decoding the Genetic Puzzle II-1
Advantages of DNA-Probe Tests II-2
Growth Drivers in a Nutshell II-2
Growth Inhibitors in a Nutshell II-2
Genetic Profiling of Pathogens: A Road Less Traveled II-3
Roche’s Entry into the Hall of Molecular Fame II-3
Non-Amplification Theory Threatens to Enervate Roche’s PCR
Forte II-3
DNA Technology: An Evolutionary Scan II-4
An Era of Excellence: Tracking Landmark Breakthroughs in
DNA Diagnostics II-5
Opportunities II-6
Market Trends/Issues II-6
Molecular Diagnostics: Promising a Bright Future II-6
DNA Tests: Finding Use in Numerous Applications II-6
World’s Aging Population Drives the Popularity of DNA-Probe
Tests II-6
Reimbursements: “Under the Umbrella” II-7
Evolution of New & Virulent Infectious Agents II-7
The Enlightened Consumer of the 21st Century II-7
Challenges In Widespread Deployment of DNA Based Diagnostics II-7
Miniaturization: An Uphill Task II-8
Improvements in Assay Capabilities II-8
Detection: A Knotty Problem II-8
Information Handling & Processing: The Soft Side of
Diagnostics II-9
Integration: The Ultimate Challenge II-9
United States: Unraveling the Country’s Edge in DNA based
Diagnostics II-9
Tools for DNA Diagnostics Program: A Boost for DNA-
Diagnostic Systems II-9

2. DNA Probes-Based Diagnostics
A Primer II-10
Diagnostic Gene Detection Products II-10
Molecular Diagnostics: A Powerful Disease Detection Tool II-10
DNA Probes-Based Products II-11
Direct Detection of Target Sequence II-11
Nucleic Acid Amplification II-11
Nucleic Acid Amplification Methods II-11
Gene Detection Using DNA Chips II-11
Gene Detection by DNA Sequencing II-12
The Dynamics of Key Enabling Technologies II-12
In Situ Hybridization II-12
PCR: Polymerase Chain Reaction II-12
Chemiluminescence II-12
Gen-Probe Tigris II-13
DNA Chips II-13
Key Players II-13
Players in Molecular Diagnostics Market II-13
Product Portfolio of Industry Majors II-14
Molecular Diagnostics
A Primer II-15
Detracting Factors II-15
The Cash Cachet II-15
Implications for Clinical Diagnostics II-16
Need of the Hour II-16
Present Potential II-16
Molecular Diagnostics: Marking the Convergence of Numerous
Technologies II-16
Impact of the Human Genome Project II-17
Molecular Diagnostics: Domain of the Developed Countries II-17
“Tailored Patient Management”: An Epitomized Future of
Molecular Diagnostics II-17
Futuristics: A Rumination II-17

3. Product Overview II-19
Background II-19
Gene Probe Technology II-19
What is DNA? II-19
DNA Probes II-19
Miniaturization: A Revolutionary Method in DNA Analysis II-20
Gene Chip Technology II-20
DNA Chips II-20
Chromosome Painting Probes II-20
Diagnostic Applications Based on DNA Probes: An Overview II-20
Infectious Diseases II-20
Respiratory Tract Infections II-21
Diagnosis of Mycoplasma II-21
DNA Probes to Detect Legionella Pneumophila II-21
Detecting Tuberculosis Through Rapid Diagnostic Tests II-21
How the Technique Works II-21
Limitations II-22
Sexually Transmitted Diseases (STDs) II-22
HIV II-22
HTLV-1 Testing II-22
Hepatitis Testing II-22
Chlamydia DNA Probes II-22
Detection of Intestinal Parasites II-23
Entamoeba Histolytica II-23
Campylobacter II-23
Salmonella II-23
Identity/Forensics II-23
DNA Profiling: A Key Forensic Tool II-23
DNA-Based Forensic Diagnostics II-24
Tracing Human Origins II-24
Assessing Genetic Predisposition of Disease II-24
Molecular HLA Testing II-24
Human Leukocyte Antigen (HLA) Typing II-24
Cancer Testing II-24
Cancer: A Deadly Disease Afflicting Millions II-25
Slow Detoxifiers: Potential Cancer Candidates II-25
Improving Cancer Surgery Through Diagnostic Tests II-25
Types of Cancer II-25
Chronic Lymphocytic Leukemia (CLL) II-25
Fludara: Recommended Treatment for CLL II-25
Breast Cancer II-26
PCR Screening Technology for Breast Cancer II-26
Eye Cancers II-26
DNA Probes to Detect Retinoblastoma II-26
Others II-26
The Ames test II-26
Genetic Testing II-27
Other Diagnostic Applications II-27
Cystic Fibrosis II-27
Malaria Testing II-27
Detection of Multidrug Resistance II-27
Bacterial Resistance to Antibiotics II-28
DNA Probes for Agriculture II-28
Gene-Based Tests II-28
ID Biomedical II-28
Velogene Rapid MRSA Test II-28
Valogene Rapid VRE Test II-28
Valogene Rapid TB Test II-28
Abbott/Vysis II-29
DNA FISH Probes for Prenatal and Other Genetics II-29
DNA FISH Probes for Microdeletion Syndromes II-29
DNA FISH probes for Oncology and Pathology II-29
WCP FISH Probes II-29
CEP Chromosome Enumeration DNA FISH Probes II-29
Related Markets II-30
Prenatal Testing II-30
Invasive Procedures II-30
Amniocentesis II-30
Chorionic Villus Sampling (CVS) II-30
Non-Invasive Procedures II-30
Alpha-Fetoprotein Test II-30
Triple Test II-31
Applied Imaging’s Prenatal Screening System II-31
Flow Cytometry II-31
Gene Therapy II-32

4. Product Developments/Introductions
Molecular Diagnostics II-33
BD Launches New BD Viper System for Automating Molecular
Diagnostic Testing Process II-33
Affymetrix Unveils New GeneChip® Scanner with Higher Capacity
Scanning II-33
Genzyme Introduces EGFR Mutation Assay for Detecting Mutations II-33
bioMйrieux Rolls Out FoodExpert-ID Molecular Multi-Detection
Test for Feed Analysis II-33
Roche Launches Amplicor HPV in Europe II-34
Bamburgh Marrsh Unveils Genetic Predisposition Kits II-34
DNAPrint Genomics Unveils DNA Forensics II-34
Vysis Announces Urovysion II-34
Vysis Unleashes DNA Probe Test II-34
Quest Diagnostics Unwraps HCV DupliType Testing II-34

5. Recent Industry Activity II-35
QIAGEN to Take Over Gentra II-35
Bayer to Divest Diagnostics Division to Siemens II-35
LGC Acquires AGOWA to Extend German Operations II-35
ENZ Receives Patent for Phosphate Labeling for Medical
Research & DNA Diagnostic Products II-36
TMC Delivers Gene Assay Reagents to Jacobi Medical Center II-36
TMC Achieves CE Mark for its Tag-It Cystic Fibrosis Test Kit II-36
Toshiba Licenses Electrochemical Detection Technology to Antara II-37
Affymetrix Licenses Multiple Patents to Invitrogen II-37
Applied Biosystems Agrees to Acquire APG II-37
Abbott Enters into Agreement with ALSI for Licensing ProGRP
Biomarker II-38
QIAGEN in Protein Crystallography Co-Marketing Agreement with
ActiveSight II-38
Warnex Acquires Pro-DNA Diagnostic II-38
Celera Genomics Gains Complete Ownership of Celera Diagnostics II-39
Gen-Probe Licenses Exclusive Rights for Diagnostic Tests
Development from University of Michigan II-39
QIAGEN Enters into Licensing Agreement with Applied Biosystems
for Real-Time PCR Technologies II-39
IGC Collaborates with Roche for Cancer Biomarker Discovery II-40
Affymetrix Acquires ParAllele BioScience II-40
QIAGEN Enters into Distribution Agreement with Osmetech
Molecular Diagnostics II-40
GlaxoSmithKline Acquires Canada-Based ID Biomedical Corp. II-40
Gen-Probe Obtains FDA Approval for APTIMA II-41
Gen-Probe Signs Purchasing Agreement with Roche II-41
MP Biomedicals Acquires Qbiogene II-41
Roche Diagnostics Signs Agreement with Multilyte Limited II-41
Roche Diagnostics Receives CE Mark Certifications for its
Three Innovative Virology Tests II-41
Roche Diagnostics Receives FDA Approval for AmpliChip CYP450 Test II-41
Ventana Launches ISH Tests II-42
Abbott Receives FDA Approval for Use of AutoVysion System II-42
Affymetrix Opts Veridex for its GeneChip® Technology II-42
Abbott Signs Distributive Agreement with BioGenex II-42
Celera Diagnostics Receives Approval to Distribute ViroSeq
HIV-1 Genotyping System II-42
Digene Announces PMAS Application Filing for Rapid Capture
System II-43
Roche Forms Alliance with decode II-43
Abbott and Celera in Strategic Alliance for In Vitro Molecular
Diagnostic ProductsII-43
Fujirebio Inks an Agreement with Yale II-43
Orchid Purchases Lifecodes II-44
Abbott Acquires Vysis II-44
Roche Partners with deCode II-44
Vysis Acquires FDA Approval for DNA-Probe Test II-44
EraGen Biosciences Grants Licenses to Bayer II-44
Boston Probes Licenses LightUp Technologies II-45

6. Focus on Select Players II-46
Abbott Laboratories (US) II-46
Affymetrix Inc (US) II-46
Applied Biosystems Group (US) II-47
Bayer Diagnostics (Germany) II-47
Becton Dickinson & Company (US) II-47
Beckman Coulter (US) II-48
bioMerieux (France) II-48
Biogenex Laboratories (US) II-48
Celera Genomics (US) II-49
Digene Corporation (US) II-49
Gen-Probe Inc (US) II-49
Genzyme Corp (US) II-50
MP Biomedicals (US) II-50
Roche Diagnostics (Switzerland) II-50
Tm Bioscience (Canada) II-50

7. Global Market Perspective II-52
Table 1: World Recent Past Current & Future Analysis for DNA
Probes-based Diagnostics by Geographic Region- US, Canada,
Japan, Europe, Asia-Pacific (excluding Japan) and Latin
America Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) II-52

Table 2: World 10-Year Perspective for DNA Probes- based
Diagnostics by Geographic Region- Percentage Breakdown of
Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan) and Latin America for Years 2000, 2005 &
2010 (includes corresponding Graph/Chart) II-52

Table 3: World Recent Past Current & Future Analysis for DNA
Probes-based Diagnostics (Infectious Disease Diagnosis) by
Geographic Region- US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan) and Latin America Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2000 through 2010 (includes corresponding Graph/Chart) II-53

Table 4: World 10-Year Perspective for DNA Probes-based
Diagnostics (Infectious Disease Diagnosis) by Geographic
Region- Percentage Breakdown of Dollar Sales for US, Canada,
Japan, Europe, Asia-Pacific (excluding Japan) and Latin
America for Years 2000, 2005 & 2010 (includes corresponding
Graph/Chart) II-53

Table 5: World Recent Past Current & Future Analysis for DNA
Probes-based Diagnostics (Cancer Diagnosis) by Geographic
Region- US, Canada, Japan, Europe, Asia-Pacific (excluding
Japan) and Latin America Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2000 through
2010 (includes corresponding Graph/Chart) II-54

Table 6: World 10-Year Perspective for DNA Probes-based
Diagnostics (Cancer Diagnosis) by Geographic Region-
Percentage Breakdown of Dollar Sales for US, Canada, Japan,
Europe, Asia-Pacific (excluding Japan) and Latin America for
Years 2000, 2005 & 2010 (includes corresponding Graph/Chart) II-54

Table 7: World Recent Past Current & Future Analysis for DNA
Probes-based Diagnostics (Genetic Predisposition Diagnosis) by
Geographic Region- US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan) and Latin America Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2000 through 2010 (includes corresponding Graph/Chart) II-55

Table 8: World 10-Year Perspective for DNA Probes-based
Diagnostics (Genetic Predisposition Diagnosis) by Geographic
Region- Percentage Breakdown of Dollar Sales for US, Canada,
Japan, Europe, Asia-Pacific (excluding Japan) and Latin
America for Years 2000, 2005 & 2010 (includes corresponding
Graph/Chart) II-55

Table 9: World Recent Past Current & Future Analysis for DNA
Probes-based Diagnostics (Identity/Forensics Diagnosis) by
Geographic Region- US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan) and Latin America Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2000 through 2010 (includes corresponding Graph/Chart) II-56

Table 10: World 10-Year Perspective for DNA Probes-based
Diagnostics (Identity/Forensics Diagnosis) by Geographic
Region- Percentage Breakdown of Dollar Sales for US, Canada,
Japan, Europe, Asia-Pacific (excluding Japan) and Latin
America for Years 2000, 2005 & 2010 (includes corresponding
Graph/Chart) II-56

Table 11: World Recent Past Current & Future Analysis for DNA
Probes-based Diagnostics (Molecular HLA Testing) by Geographic
Region- US, Canada, Japan, Europe, Asia-Pacific (excluding
Japan) and Latin America Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2000 through
2010 (includes corresponding Graph/Chart) II-57

Table 12: World 10-Year Perspective for DNA Probes-based
Diagnostics (Molecular HLA) by Geographic Region- Percentage
Breakdown of Dollar Sales for US, Canada, Japan, Europe,
Asia-Pacific (excluding Japan) and Latin America for Years
2000, 2005 & 2010 (includes corresponding Graph/Chart) II-57

Table 13: World Recent Past Current & Future Analysis for DNA
Probes-based Diagnostics in Other Types of Diagnosis by
Geographic Region- US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan) and Latin America Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2000 through 2010 (includes corresponding Graph/Chart) II-58

Table 14: World 10-Year Perspective for DNA Probes- based
Diagnostics in Other Types of Diagnosis by Geographic Region-
Percentage Breakdown of Dollar Sales for US, Canada, Japan,
Europe, Asia-Pacific (excluding Japan) and Latin America for
Years 2000, 2005 & 2010 (includes corresponding Graph/Chart) II-58


III. MARKET

1. The United States III-1
A.Market Analysis III-1
Outlook III-1
United States: Unraveling the Country’s Edge in DNA based
Diagnostics III-1
Tools for DNA Diagnostics Program: A Boost for DNA-
Diagnostic Systems III-1
STD (Sexually Transmitted Diseases) Tests Segment III-2
Review of Leading Players III-2
Product Launches III-6
Strategic Developments III-9
Historical Perspective III-16
Technological Developments III-16
Product Launches III-18
Strategic Developments III-19
B.Market Analytics III-26
Table 15: US Recent Past, Current & Future Analysis for DNA
Probes-based Diagnostics by Application Area- Infectious
Diseases, Cancer, Genetic Predisposition,
Identity/Forensics, Molecular HLA Testing, and Others
Markets Independently Analyzed with Annual Sales Figures
in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-26

Table 16: US 10-Year Perspective for DNA Probes- based
Diagnostics by Application Area Percentage Breakdown of
Dollar Sales for Infectious Diseases, Cancer, Genetic
Predisposition, Identity/Forensics, Molecular HLA Testing,
and Others Markets for 2000, 2005 & 2010 (includes
corresponding Graph/Chart) III-26

2. Canada III-27
A.Market Analysis III-27
Outlook III-27
Review of Leading Players III-27
Strategic Developments III-27
B.Market Analytics III-29
Table 17: Canadian Recent Past, Current & Future Analysis
for DNA Probes-based Diagnostics by Application Area-
Infectious Diseases, Cancer, Genetic Predisposition,
Identity/Forensics, Molecular HLA Testing, and Others
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-29

Table 18: Canadian 10-Year Perspective for DNA Probes-based
Diagnostics by Application Area Percentage Breakdown of
Dollar Sales for Infectious Diseases, Cancer, Genetic
Predisposition, Identity/Forensics, Molecular HLA Testing,
and Others Markets for 2000, 2005 & 2010 (includes
corresponding Graph/Chart) III-29

3. Japan III-30
A.Market Analysis III-30
Outlook III-30
Strategic Developments III-30
Historic Developments III-30
B.Market Analytics III-31
Table 19: Japanese Recent Past, Current & Future Analysis
for DNA Probes-based Diagnostics by Application Area-
Infectious Diseases, Cancer, Genetic Predisposition,
Identity/Forensics, Molecular HLA Testing, and Others
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-31

Table 20: Japanese 10-Year Perspective for DNA Probes-based
Diagnostics by Application Area Percentage Breakdown of
Dollar Sales for Infectious Diseases, Cancer, Genetic
Predisposition, Identity/Forensics, Molecular HLA Testing,
and Others Markets for 2000, 2005 & 2010 (includes
corresponding Graph/Chart) III-31

4. Europe III-32
A.Market Analysis III-32
Outlook III-32
Strategic Developments III-32
B.Market Analytics III-33
Table 21: European Recent Past, Current & Future Analysis
for DNA Probes-based Diagnostics by Geographic Region -
France, Germany, Italy, UK and Rest of Europe Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2000 through 2010 (includes corresponding
Graph/Chart) III-33

Table 22: European 10-Year Perspective for DNA Probes-based
Diagnostics by Geographic Region
Percentage Breakdown of
Dollar Sales for France, Germany, Italy, UK and Rest of
Europe Markets for Years 2000, 2005 & 2010 (includes
corresponding Graph/Chart) III-33

Table 23: European Recent Past, Current & Future Analysis
for DNA Probes-based Diagnostics by Application Area-
Infectious Diseases, Cancer, Genetic Predisposition,
Identity/Forensics, Molecular HLA Testing, and Others
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-34

Table 24: European 10-Year Perspective for DNA Probes-based
Diagnostics by Application Area Percentage Breakdown of
Dollar Sales for Infectious Diseases, Cancer, Genetic
Predisposition, Identity/Forensics, Molecular HLA Testing,
and Others Markets for 2000, 2005 & 2010 (includes
corresponding Graph/Chart) III-34

4a. France III-35
A.Market Analysis III-35
Outlook III-35
Key Player III-35
Product Launch III-35
Historic Development III-35
B.Market Analytics III-36
Table 25: French Recent Past, Current & Future Analysis for
DNA Probes-based Diagnostics by Application Area- Infectious
Diseases, Cancer, Genetic Predisposition,
Identity/Forensics, Molecular HLA Testing, and Others
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-36

Table 26: French 10-Year Perspective for DNA Probes-based
Diagnostics by Application Area Percentage Breakdown of
Dollar Sales for Infectious Diseases,Cancer, Genetic
Predisposition, Identity/Forensics, Molecular HLA Testing,
and Others Markets for 2000, 2005 & 2010 (includes
corresponding Graph/Chart) III-36

4b. Germany III-37
A.Market Analysis III-37
Outlook III-37
Key Player III-37
Strategic Developments III-37
Historic Development III-38
B.Market Analytics III-38
Table 27: German Recent Past, Current & Future Analysis for
DNA Probes-based Diagnostics by Application Area- Infectious
Diseases, Cancer, Genetic Predisposition,
Identity/Forensics, Molecular HLA Testing, and Others
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-38

Table 28: German 10-Year Perspective for DNA Probes-based
Diagnostics by Application Area Percentage Breakdown of
Dollar Sales for Infectious Diseases, Cancer, Genetic
Predisposition, Identity/Forensics, Molecular HLA Testing,
and Others Markets for 2000, 2005 & 2010 (includes
corresponding Graph/Chart) III-39

4c. Italy III-40
Market Analysis III-40
Table 29: Italian Recent Past, Current & Future Analysis for
DNA Probes-based Diagnostics by Application Area- Infectious
Diseases, Cancer, Genetic Predisposition,
Identity/Forensics, Molecular HLA Testing, and Others
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-40

Table 30: Italian 10-Year Perspective for DNA Probes-based
Diagnostics by Application Area- Percentage Breakdown of
Dollar Sales for Infectious Diseases, Cancer, Genetic
Predisposition, Identity/Forensics, Molecular HLA Testing,
and Others Markets for 2000, 2005 & 2010 (includes
corresponding Graph/Chart) III-41

4d. The United Kingdom III-42
A.Market Analysis III-42
Outlook III-42
Strategic Development III-42
Historic Developments III-42
B.Market Analytics III-43
Table 31: UK Recent Past, Current & Future Analysis for DNA
Probes-based Diagnostics by Application Area- Infectious
Diseases, Cancer, Genetic Predisposition,
Identity/Forensics, Molecular HLA Testing, and Others
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-43

Table 32: UK 10-Year Perspective for DNA Probes- based
Diagnostics by Application Area- Percentage Breakdown of
Dollar Sales for Infectious Diseases, Cancer, Genetic
Predisposition, Identity/Forensics, Molecular HLA Testing,
and Others Markets for 2000, 2005 & 2010 (includes
corresponding Graph/Chart) III-43

4e. Rest of Europe III-44
A.Market Analysis III-44
Outlook III-44
Clinical Diagnostics in Russia III-44
Key Player III-44
Strategic Developments III-45
Historic Developments III-46
B.Market Analytics III-47
Table 33: Rest of Europe Recent Past, Current & Future
Analysis for DNA Probes-based Diagnostics by Application
Area
Infectious Diseases, Cancer, Genetic Predisposition,
Identity/Forensics, Molecular HLA Testing, and Others
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-47

Table 34: Rest of Europe 10-Year Perspective for DNA
Probes-based Diagnostics by Application Area- Percentage
Breakdown of Dollar Sales for Infectious Diseases, Cancer,
Genetic Predisposition, Identity/Forensics, Molecular HLA
Testing, and Others Markets for 2000, 2005 & 2010 (includes
corresponding Graph/Chart) III-47

5. Asia-Pacific III-48
A.Market Analysis III-48
Outlook III-48
Historic Development III-48
B.Market Analytics III-48
Table 35: Asia-Pacific Recent Past, Current & Future
Analysis for DNA Probes-based Diagnostics by Application
Area- Infectious Diseases, Cancer, Genetic Predisposition,
Identity/Forensics, Molecular HLA Testing, and Others
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-48

Table 36: Asia-Pacific 10-Year Perspective for DNA
Probes-based Diagnostics by Application Area- Percentage
Breakdown of Dollar Sales for Infectious Diseases, Cancer,
Genetic Predisposition, Identity/Forensics, Molecular HLA
Testing, and Others Markets for 2000, 2005 & 2010 (includes
corresponding Graph/Chart) III-49

6. Latin America III-50
Market Analysis III-50
Table 37: Latin American Recent Past, Current & Future
Analysis for DNA Probes-based Diagnostics by Application
Area- Infectious Diseases, Cancer, Genetic Predisposition,
Identity/Forensics, Molecular HLA Testing, and Others
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-50

Table 38: Latin American 10-Year Perspective for DNA
Probes-based Diagnostics by Application Area- Percentage
Breakdown of Dollar Sales for Infectious Diseases, Cancer,
Genetic Predisposition, dentity/ Forensics, Molecular HLA
Testing, and Others Markets for 2000, 2005 & 2010 (includes
corresponding Graph/Chart) III-51


IV. COMPETITION

1. Abbott Laboratories (USA) IV-1
Table 39: Half Yearly Sales Analysis by Quarters:
2005-2006 (H1) (In US$ million) IV-3

Table 40: Half Yearly Sales Analysis by Business
Segment: 2005-2006 (H1) (In US$ million) IV-3

Table 41: Annual Sales Analysis by Quarter: 2004-2005
(In US$ million) IV-3

Table 42: Annual Sales Analysis by Business Segment:
2004-2005 (In US$ million) IV-3

Table 43: Annual Sales Analysis by Geographic Region:
2004-2005 (In US$ million) IV-4
Abbott Diagnostics Division of Abbott Laboratories (USA) IV-12
2. ActiveSight (USA) IV-16
3. Advanced Life Science Institute, Inc. (ALSI) (Japan) IV-18
4. Affymetrix, Inc. (USA) IV-19
Table 44: Half Yearly Sales Analysis: 2005-2006 (H1)
(In US$ million) IV-20

Table 45: Quarterly Sales Analysis: 2005-2006 (H1) (In
US$ million) IV-20

Table 46: Annual Sales Analysis: 2004-2005 (In US$
million) IV-20
5. Antara BioSciences, Inc. (USA) IV-25
6. Applied Biosystems (USA) IV-26
Table 47: Nine Months Sales Analysis by Quarter:
2005-2006 (Nine Months Ended, March) (In US$ billion) IV-27

Table 48: Nine Months Sales Analysis by Product
Segment: 2005-2006 (Nine Months Ended, March) (In US$
billion) IV-27

Table 49: Nine Months Sales Analysis by Business
Segment: 2005-2006 (Nine Months Ended, March) (In US$
billion) IV-27

Table 50: Nine Months Sales Analysis by Geographic
Region: 2005-2006 (Nine Months Ended, March) (In US$
billion) IV-27

Table 51: Quarterly Sales Analysis: 2004-2005 (In US$
billion) IV-28

Table 52: Annual Sales Analysis by Product Segment:
2004-2005 (In US$ billion) IV-28

Table 53: Annual Sales Analysis by Business Segment:
2004-2005 (In US$ billion) IV-28

Table 54: Annual Sales Analysis by Geographic Region:
2004-2005 (In US$ billion) IV-28
7. Bayer Healthcare, Diagnostics Division (USA) IV-33
8. Beacon Diagnostics, Inc. (USA) IV-38
9. Beckman Coulter, Inc. (USA) IV-39
Table 55: Half Yearly Sales Analysis: 2005-2006 (H1)
(In US$ million) IV-43

Table 56: Quarterly Sales Analysis: 2005-2006 (H1) (In
US$ million) IV-43

Table 57: Half Yearly Sales Analysis by Business
Segment: 2005-2006 (H1) (In US$ million) IV-43
Table 58: Half Yearly Sales Analysis by Geographical
Region: 2005-2006 (H1) (In US$ million) IV-43
Table 59: Annual Sales Analysis by Business Segment:
2004-2005 (In US$ million) IV-43

Table 60: Annual Sales Analysis by Geographical Region:
2004-2005 (In US$ million) IV-44

Table 61: Quarterly Sales Analysis: 2004-2005 (In US$
million) IV-44
10. Becton Dickinson and Company (USA) IV-47
Table 62: Half Yearly Sales Analysis: 2005-2006 (H1)
(In US$ million) IV-49

Table 63: Half Yearly Sales Analysis by Segment:
2005-2006 (H1) (In US$ million) IV-49

Table 64: Annual Sales Analysis: 2004-2005 (In US$
million) IV-49
BD Diagnostic Systems (USA) IV-52
11. Biogenex Laboratories, Inc. (USA) IV-55
12. bioMerieux SA (France) IV-58
Biomerieux, Inc. (USA) IV-63
13. Biotest AG (Germany) IV-66
Biotest Diagnostics Corporation (USA) IV-67
14. Celera Diagnostics (USA) IV-70
15. Celltech Group PLC (UK) IV-72
16. Chiron Corporation (USA) IV-73
17. Cytogen Corporation (USA) IV-80
Table 65: Half Yearly Sales Analysis by Business
Operations: 2005-2006 (H1) (In US$ million) IV-80
Table 66: Quarterly Sales Analysis: 2004-2005 (In US$
million) IV-81

Table 67: Annual Sales Analysis by Business Operations:
2004-2005 (In US$ million) IV-81
18. Dade Behring Holdings, Inc. (USA) IV-84
Table 68: Half Yearly Sales Analysis by Segment:
2005-2006 (H1) (In US$ million) IV-85

Table 69: Half Yearly Sales Analysis by Geographic
Region: 2005-2006 (H1) (In US$ million) IV-85

Table 70: Annual Sales Analysis by Quarter: 2004-2005
(In US$ million) IV-86

Table 71: Annual Sales Analysis by Segment: 2004-2005
(In US$ million) IV-86

Table 72: Annual Sales Analysis by Geographic Region:
2004-2005 (In US$ million) IV-86
19. DiaSorin, Inc. (USA) IV-89
20. Digene Corporation (USA) IV-90
Table 73: Nine Months Sales Analysis: 2005-2006 (Nine
Months Ended March) (In US$ million) IV-90

Table 74: Annually Sales Analysis by Quarter: 2004-2005
(In US$ million) IV-91
21. Enzo Life Sciences, Inc. (USA) IV-94
22. Gen-Probe, Inc. (USA) IV-99
Table 75: Half Yearly Sales Analysis: 2005-2006 (H1)
(In US$ million) IV-99

Table 76: Annual Sales Analysis by Segment: 2004-2005
(In US$ million) IV-100

Table 77: Annual Sales Analysis by Geographic Region:
2004-2005 (In US$ million) IV-100
23. Gentra Systems, Inc. (USA) IV-105
24. Genzyme Corporation (USA) IV-107
Table 78: Half Yearly Sales Analysis: 2005-2006 (H1)
(In US$ million) IV-110

Table 79: Half Yearly Sales Analysis by Quarter:
2005-2006 (H1) (In US$ million) IV-110

Table 80: Half Yearly Sales Analysis by Segment:
2005-2006 (H1) (In US$ million) IV-110

Table 81: Annual Sales Analysis: 2004-2005 (In US$
million) IV-110

Table 82: Annual Sales Analysis by Quarter: 2004-2005
(In US$ million) IV-111

Table 83: Annual Sales Analysis by Segment: 2004-2005
(In US$ million) IV-111

Table 84: Annual Sales Analysis by Geographic Region:
2004-2005 (In US$ billion) IV-111
25. Glaxosmithkline PLC (UK) IV-117
Table 85: Half Yearly Sales Analysis: 2005-2006 (H1)
(In Ј million) IV-118

Table 86: Half Yearly Sales Analysis by Segment:
2005-2006 (H1) (In Ј million) IV-118

Table 87: Annual Sales Analysis: 2004-2005 (In Ј
million) IV-118

Table 88: Annual Sales Analysis by Segment: 2004-2005
(In Ј million) IV-119
26. Healthgene Corporation (Canada) IV-128
27. Idaho Technology, Inc. (USA) IV-129
28. Idexx Laboratories, Inc. (USA) IV-132
Table 89: Nine Months Sales Analysis: 2005-2006 (Nine
Months Ended, September) (In US$ million) IV-134

Table 90: Quarterly Sales Analysis: 2005-2006 (Nine
Months Ended, September) (In US$ million) IV-134

Table 91: Nine Months Sales Analysis by Business
Segment: 2005-2006 (Nine Months Ended, September) (In
US$ million) IV-134

Table 92: Annual Sales Analysis: 2004-2005 (In US$
million) IV-134

Table 93: Annual Sales Analysis by Business Segment:
2004-2005 (In US$ million) IV-135

Table 94: Annual Sales Analysis by Geographical Region:
2004-2005 (In US$ million) IV-135

Table 95: Quarterly Sales Analysis: 2004-2005 (In US$
million) IV-135
29. Innogenetics NV (Belgium) IV-140
30. LGC Limited (UK) IV-149
AGOWA (Germany) IV-154
31. Millipore Corporation (USA) IV-156
Table 96: Half Yearly Sales Analysis by Quarter:
2005-2006 (H1) (In US$ million) IV-157

Table 97: Half Yearly Sales Analysis by Business
Segment: 2005-2006 (H1) (In US$ million) IV-157
Table 98: Half Yearly Sales Analysis by Geographical
Region: 2005-2006 (H1) (In US$ million) IV-157
Table 99: Annual Sales Analysis: 2004-2005 (In US$
million) IV-157

Table 100: Annual Sales Analysis by Business Segment:
2004-2005 (In US$ million) IV-157

Table 101: Annual Sales Analysis by Geographical
Region: 2004-2005 (In US$ million) IV-158

Table 102: Quarterly Sales Analysis: 2004-2005 (In US$
million) IV-158
Chemicon International, Inc. (USA) IV-164
32. MP Biomedicals (USA) IV-168
33. Myriad Genetics, Inc. (USA) IV-170
Table 103: Nine Months Sales Analysis by Quarter:
2005-2006 (Nine Months Ended, March) (In US$ million) IV-171

Table 104: Nine Months Sales Analysis by Segment:
2005-2006 (Nine Months Ended, March) (In US$ million) IV-171

Table 105: Annual Sales Analysis: 2004-2005 (In US$
million) IV-171

Table 106: Annual Sales Analysis by Quarter: 2004-2005
(In US$ million) IV-171

Table 107: Annual Sales Analysis by Segment: 2004-2005
(In US$ million) IV-172
34. Osmetech, Inc.
Critical Care Division (USA) IV-173
35. PerkinElmer, Inc. (USA) IV-175
Table 108: Half Yearly Sales Analysis by Quarter:
2005-2006 (H1) (In US$ million) IV-177

Table 109: Half Yearly Sales Analysis by Business
Segment: 2005-2006 (H1) (In US$ million) IV-177

Table 110: Annual Sales Analysis: 2003-2005 (In US$
million) IV-177

Table 111: Annual Sales Analysis by Quarter: 2004-2005
(In US$ million) IV-177

Table 112: Annual Sales Analysis by Business Segment:
2004-2005 (In US$ million) IV-178

Table 113: Annual Sales Analysis by Geographic Region:
2004-2005 (In US$ million) IV-178
36. Promega Corporation (USA) IV-188
37. Qbiogene, Inc. (USA) IV-189
38. Qiagen GmbH (Germany) IV-192
39. Roche Diagnostics AG (Switzerland) IV-199
Table 114: Annual Sales Analysis: 2005-2006 (In CHF
million) IV-200
Roche Diagnostics Corporation (USA) IV-202
Roche Diagnostics (Deutschland) GmbH (Germany) IV-204
40. Sigma-Genosys, Ltd. (UK) IV-205
41. Signet Laboratories, Inc. (USA) IV-206
42. Therion International, LLC (USA) IV-207
43. TM Bioscience Corporation (Canada) IV-208
Table 115: First Quarter Sales Analysis: 2005-2006 (Q1)
(In Can$ million) IV-209

Table 116: Annual Sales Analysis: 2004-2005 (In Can$
million) IV-209

Table 117: Annual Sales Analysis by Quarter: 2004-2005
(In Can$ million) IV-209
44. Ventana Medical Systems, Inc. (USA) IV-213
Table 118: Half Yearly Sales Analysis by Quarter:
2005-2006 (H1) (In US$ million) IV-214
Table 119: Half Yearly Sales Analysis by Geographic
Region: 2005-2006 (H1) (In US$ million) IV-214
Table 120: Annual Sales Analysis: 2004-2005 (In US$
million) IV-214

Table 121: Annual Sales Analysis by Quarter: 2004-2005
(In US$ million) IV-214

Table 122: Annual Sales Analysis by Segment: 2004-2005
(In US$ million) IV-214

Table 123: Annual Sales Analysis by Geographic Region:
2004-2005 (In US$ million) IV-215
45. Veridex LLC (USA) IV-219
46. Warnex (Canada) IV-220
Table 124: Half Yearly Sales Analysis: 2005-2006 (H1)
(In US$ million) IV-220




Order this report

  Company name:
  Contact person:
  Phone/fax:
  Email:
  Comments:
   


Product Trade Lead
0 leads found


Add New Buy/Sell Lead

© 2007-2010 MarketReportFinder.com